Method for establishing antigen-specific T cell induced type 1 diabetes animal model

By injecting T cells with specific GAD and low-dose STZ into non-immune-deficient mice, an antigen-specific T cell-induced T1DM model was constructed, which solved the problem that the existing model could not truly simulate human pathology and achieved non-immune The effect of inducing T1DM in defective animals has promoted T1DM research and drug development.

CN118985533AActive Publication Date: 2024-11-22SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310550871.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-16
Publication Date
2024-11-22
Estimated Expiration
2043-05-16

AI Technical Summary

Technical Problem

The existing animal models of type 1 diabetes (T1DM) cannot truly simulate human pathological processes in non-immunely deficient wild-type animals. The NOD mouse model has immunodeficiency problems, while the chemical induction model mainly causes damage to beta cells rather than autoimmunity. disease.

Method used

An antigen-specific T-cell-induced T-cell T-cells were constructed by injecting T cells specifically targeting GAD to non-immune-deficient mice and inducing the destruction of pancreatic islet β cells in combination with low doses of streptozotocin (STZ).

Benefits of technology

The formation of an autoreactive T1DM model was successfully induced in non-immunely deficient mice, which was consistent with the actual pathogenesis, made up for the insufficient immunodeficiency of NOD mouse models, and helped better study the pathogenesis of T1DM and screen the therapeutic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004231398040000011
    Figure HDA0004231398040000011
  • Figure HDA0004231398040000012
    Figure HDA0004231398040000012
  • Figure HDA0004231398040000021
    Figure HDA0004231398040000021
Patent Text Reader

Abstract

The invention provides a preparation method of a type 1 diabetes non-human mammal model. Specifically, by using T cells specifically targeting GAD, pancreatic beta cell destruction is induced in non-immunodeficient mice, the T cell autoimmune type 1 diabetes mellitus conforming to actual pathogenesis is constructed, and the application prospect in the field of diabetes mellitus research is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological models, and in particular to a method for establishing an antigen-specific T cell-induced type 1 diabetes animal model. Background Art

[0002] Type 1 diabetes mellitus (T1DM) is an organ-specific autoimmune disease characterized by inflammatory infiltration of the pancreatic islets and autoreactive immune cells, especially T cells, which continuously destroy pancreatic β cells, resulting in the inability to produce enough insulin to maintain the homeostasis of blood glucose metabolism, resulting in symptoms such as hyperglycemia. T1DM animal models have greatly promoted research on the pathogenesis of T1DM and drug development. Among them, the commonly used T1DM research models include the NOD mouse model and chemical substances, such as streptozotocin (STZ) or alloxan, which are injected to induce T1DM models. The T1DM phenotype of NOD mice is caused by genetic defects. The mice show multiple immune phenotype abnormalities, including defects in the immune regulation of antigen presenting cells, defects in the regulation of T lymphocytes, and defects in NK cell function. Therefore, they cannot truly simulate the pathology of the T1DM population. The T1DM model induced by injection of drugs such as STZ is mainly due to the direct destruction of β cells by chemical substances, rather than autoimmunity causing T1DM.

[0003] Therefore, in order to better promote related research and drug development, this field still needs to develop a method for constructing a T1DM animal model that can simulate the pathological process of the T1DM population in non-immunodeficient wild-type animals. Summary of the invention

[0004] The purpose of the present invention is to provide a method for constructing a wild-type T1DM animal model.

[0005] In a first aspect of the present invention, a method for preparing a type 1 diabetes non-human mammal model is provided, wherein the animal is a non-immunodeficient animal, and the method comprises administering T cells specifically targeting GAD to the animal.

[0006] In another preferred embodiment, the animal is a rodent or a primate, preferably including mice, rats, rabbits, and monkeys.

[0007] In another preferred embodiment, the animal is a C57BL / 6 mouse.

[0008] In another preferred embodiment, the T cells are prepared by the following method:

[0009] A cell population is provided which is immunostimulated with a GAD antigen peptide, and T cells are isolated from the cell population.

[0010] In another preferred embodiment, the immune stimulation includes in vivo immune stimulation or in vitro immune stimulation.

[0011] In another preferred embodiment, the immune stimulation includes stimulation with a GAD antigen peptide having an amino acid sequence such as AFLHATDLL (SEQ ID NO. 1) or YAFLHATDL (SEQ ID NO. 2).

[0012] In another preferred embodiment, the T cells specifically targeting GAD specifically bind to an antigen epitope peptide as shown in AFLHATDLL (SEQ ID NO.1).

[0013] In another preferred embodiment, the T cells are CD4 + T cells, CD8 + T cells, or a combination thereof.

[0014] In another preferred embodiment, the T cells are CD8 + T cells.

[0015] In another preferred embodiment, the amount of T cells does not exceed 5×10^6 cells / animal, preferably does not exceed 3×10^6 cells / animal, and more preferably does not exceed 1×10^6 cells / animal.

[0016] In another preferred embodiment, the method further comprises administering a compound selected from the following group:

[0017] STZ, alloxan, or a combination thereof.

[0018] In another preferred embodiment, the total amount of STZ administered is no more than 300 mg / kg body weight, preferably no more than 200 mg / kg body weight, more preferably no more than 150 mg / kg body weight, and more preferably no more than 80 mg / kg body weight.

[0019] In another preferred embodiment, the single administration amount of STZ does not exceed 80 mg / kg body weight, preferably does not exceed 60 mg / kg body weight, and more preferably does not exceed 40 mg / kg body weight.

[0020] In another preferred example, in the animal, the number of pancreatic β cells decreases, preferably decreases by more than 50%, more preferably decreases by more than 80%.

[0021] In another preferred embodiment, the decrease in the number of pancreatic β cells is caused by T cell-specific killing.

[0022] In the second aspect of the present invention, there is provided use of the animal model prepared by the method described in the first aspect of the present invention for studying the pathogenesis of T1DM.

[0023] In the third aspect of the present invention, there is provided use of the animal model prepared by the method described in the first aspect of the present invention for screening or identifying substances that can prevent or treat T1DM.

[0024] In a fourth aspect of the present invention, a method for preparing GAD-specific T cells is provided, the method comprising the steps of:

[0025] 1) providing a cell population stimulated by GAD immunotherapy, and isolating a T cell population from the cell population;

[0026] 2) isolating T cells that specifically bind to the antigen peptide shown in SEQ ID NO.1 from the T cell population.

[0027] In another preferred embodiment, the separation comprises separating GAD-specific T cells from the T cell population using an MHC-antigen peptide complex, wherein the antigen peptide sequence contains a sequence as shown in SEQ ID NO.1.

[0028] In another preferred embodiment, the cell population can be obtained by in vivo or in vitro immune stimulation.

[0029] In another preferred embodiment, the immune stimulation includes stimulation with a GAD antigen peptide having an amino acid sequence such as AFLHATDLL (SEQ ID NO. 1) or YAFLHATDL (SEQ ID NO. 2).

[0030] In another preferred embodiment, the T cells are CD8 + T cells.

[0031] In another preferred embodiment, the cell population is from animals or artificially cultured.

[0032] In another preferred embodiment, the cell population is from an animal selected from the group consisting of mice, rats, and humans.

[0033] In another preferred embodiment, the cell population is selected from the following group: peripheral blood mononuclear cells (PBMC), spleen lymphocytes or monocytes, pancreatic drainage lymphocytes, pancreatic immune infiltrating cells, or a combination thereof.

[0034] In the fifth aspect of the present invention, a GAD-specific T cell is provided, wherein the T cell is prepared by the method described in the fourth aspect of the present invention.

[0035] In a sixth aspect of the present invention, a method for screening or identifying a potential therapeutic agent for preventing or treating T1DM is provided, comprising the steps of:

[0036] (a) in a test group, in the presence of the test compound, administering the test compound to the animal model prepared by the method described in the first aspect of the invention, and monitoring the blood glucose level G1 of the animal model in the test group; in a control group, in the absence of the test compound, administering a control compound (such as a solvent) to the animal model prepared by the method described in the first aspect of the invention, and monitoring the blood glucose level G2 of the animal model in the test group;

[0037] (b) comparing the blood glucose values ​​G1 and G2 detected in the previous step to determine whether the test compound is a potential therapeutic agent for preventing and / or treating T1DM;

[0038] If the blood glucose level G1 is significantly lower than the blood glucose level G2, it indicates that the test compound is a potential therapeutic agent for preventing and / or treating T1DM.

[0039] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

[0040] In the seventh aspect of the present invention, a T1DM model of a non-human mammal is provided, wherein the model is prepared by the method described in the first aspect of the present invention.

[0041] In an eighth aspect of the present invention, a composition for preparing a T1DM non-human mammal model is provided, the composition comprising:

[0042] M1) T cells that specifically target GAD; and

[0043] M2) Other substances that induce T1DM.

[0044] In another preferred embodiment, the M2 includes STZ, alloxan, or a combination thereof.

[0045] In another preferred embodiment, the T cells specifically targeting GAD specifically bind to an antigen epitope peptide as shown in AFLHATDLL (SEQ ID NO.1).

[0046] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] The following drawings are used to illustrate specific embodiments of the present invention and are not used to limit the scope of the present invention defined by the claims.

[0048] Figure 1The blood glucose concentration curves of mice are shown. *p<0.05, ***p<0.001, ****p<0.0001; n=5.

[0049] Figure 2 Immunofluorescence staining showing the content of β cells in the pancreas is shown: (A) Representative islets from the adoptively transferred (AT) immune cell group, (B) Representative islets from the PBS group. MAFA (green), DAPI (blue). Scale bar: 50 μm.

[0050] Figure 3 Pancreatic immunofluorescence is shown. AT, representative islets from the adoptively transferred immune cell group, PBS, representative islets from the PBS-injected group immunofluorescence staining. CD3 (green), glucagon (red), DAPI (blue). Scale bar: 50 μm.

[0051] Figure 4 A flow chart of adoptive immunization of the present invention is shown. DETAILED DESCRIPTION

[0052] After extensive and in-depth research, the inventors have developed for the first time a method for establishing an animal model of type 1 diabetes induced by antigen-specific T cells. Wild-type mice (e.g., C57BL / 6) are immunized by injecting pancreatic autoantigens so that the mice contain abundant pancreatic autoantigen-specific T cells. After separation and purification, pancreatic autoantigen-specific T cells are obtained, which are adoptively transferred into healthy mice of the same strain to induce mice to progress to type 1 diabetes (T1DM), thereby constructing an autoimmune T1DM model induced by antigen-specific T cells. On this basis, the present invention has been completed.

[0053] GAD

[0054] Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme that catalyzes the conversion of glutamate to GABA, the major inhibitory neurotransmitter in the central nervous system. In addition to being found in all GABAergic neurons, GAD has also been detected in pancreatic islet cells.

[0055] There are two isomers of GAD in mammals, GAD65 and GAD67. The two are basically similar in structure, but have different stereo conformations and antigenic epitopes. GAD65 is mainly present in the pancreas, while GAD67 is mainly present in brain tissue.

[0056] GAD65 full-length sequence (Mus musculus, mouse):

[0057] (SEQ ID NO.3)

[0058] The present invention uses T cells that specifically target GAD to construct a T1DM model. The T cells of the present invention can be any T cells that specifically bind to the GAD protein, for example, can be T cells that specifically recognize the epitope sequence AFLHATDLL (SEQ ID NO.1, positions 90-98 of the GAD65 protein).

[0059] The GAD-specific T cells used in the present invention can be prepared using the following steps:

[0060] 1) providing a cell population stimulated by GAD immunotherapy, and isolating a T cell population from the cell population;

[0061] 2) Using the MHC-antigen peptide complex to separate GAD-specific T cells from the T cell population, wherein the antigen peptide sequence is shown in SEQ ID NO.1.

[0062] The T cells of the present invention can be derived from a cell population of the following sources: peripheral blood mononuclear cells (PBMC), spleen lymphocytes or monocytes, pancreatic drainage lymphocytes, pancreatic immune infiltrating cells, or a combination thereof. The cell population can be derived from an animal or artificially cultured. The cell population is derived from an animal selected from the group consisting of mice, rats, and humans. The cell population can be obtained by in vivo or in vitro immune stimulation, including stimulation with a GAD antigen peptide having an amino acid sequence such as AFLHATDLL (SEQ ID NO.1) or YAFLHATDL (SEQ ID NO.2).

[0063] Animal models

[0064] In the present invention, a non-human mammal model of type 1 diabetes (T1DM) is provided. The T1DM animal model of the present invention is an autoimmune T1DM model induced by antigen-specific T cells.

[0065] In the present invention, examples of non-human mammals include (but are not limited to): mice, rats, rabbits, monkeys, etc., more preferably rats and mice.

[0066] The method of the present invention can prepare a T1DM model in a non-immunodeficient non-human mammal, such as a wild-type animal, preferably a C57BL / 6 mouse, but not limited thereto. It should be understood that the composition and method of the present invention can also be used to construct a T1DM model in an immunodeficient animal, so the present invention can also be applied to the model construction of Kunming mice, BALB / C mice, NOD mice, and NOD / SCID mice, but not limited thereto.

[0067] In one embodiment of the present invention, the animal model of the present invention is constructed by co-administering M1) T cells that specifically target GAD; and M2) other chemical substances (such as STZ).

[0068] The inventors have found through research that, in non-immunodeficient mice, streptozotocin does not have the function of inducing T1DM when administered at low doses and low frequencies (such as a total dose not exceeding 100 mg / kg), and the percentage of pancreatic β cells in mice after administration is normal; however, when it is used in combination with GAD-specific T cells, it can effectively induce pancreatic β cell destruction in non-immunodeficient mice, thereby constructing a T1DM model that conforms to the actual pathogenesis.

[0069] The main advantages of the present invention include:

[0070] 1) Compared with the NOD mouse model, the specific T cells of the present invention can induce the formation of an autoreactive T1DM model in mice with normal immune systems (such as C57BL / 6 mice), which makes up for the shortcomings of NOD mice that have immune deficiency and cannot reflect the real pathology;

[0071] 2) The present invention found that low-dose and low-frequency administration of STZ alone does not cause disease, but can promote specific T-cell-induced autoimmune reactions, thereby destroying pancreatic β cells; this method is more consistent with the pathogenesis of T1DM than single-dose STZ for multiple small-dose chemical induction of β cell death;

[0072] 3) The modeling method of the present invention is conducive to better clarifying the pathogenesis of T1DM, promoting the search for targets and methods for T1DM immunotherapy, and screening drugs for treating T1DM.

[0073] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0074] Experimental Materials:

[0075] T cell isolation kit (STEMCELL)

[0076] CD8 T Cell Isolation Kit (STEMCELL)

[0077] Isolation of MHC tetramers of antigen-specific T cells (Haozhi Biotechnology)

[0078] C57BL / 6 mice (Jicui Yaokang)

[0079] Immune emulsion CFA (Chondrex)

[0080] Antigenic peptide (Sangong Biological)

[0081] Blood glucose monitor (Roche)

[0082] OCT(Sakura)

[0083] 30% sucrose solution: weigh 30 g sucrose, dissolve it in 1× PBS solution, and make up to 100 ml.

[0084] The dilution ratio of anti-glucagon antibody (abcam) was 1:500.

[0085] The dilution ratio of anti-CD3 antibody (CST) was 1:400.

[0086] The dilution ratio of MAFA antibody (CST) was 1:400.

[0087] 0.5M citrate buffer, pH 4.5 (Beijing Tian Enze)

[0088] Example 1 Immunization of animals and T cell screening

[0089] 1.1 Preparation of antigen peptide emulsion

[0090] (1) The freeze-dried antigen peptide was diluted with PBS to 2 mg / ml. Usually, 200 μg of GAD65 antigen peptide was required for each mouse (0.1 ml of the diluted solution). The antigen peptide solution was stored at -20°C.

[0091] (2) Antigenic peptide and CFA were injected into each mouse at a ratio of 1:1 (100 μl each). Considering the loss of viscous emulsion during preparation and injection, 1.5-2 times the required amount was prepared (for example, for a total of 10 mice, 1 ml of antigenic peptide and CFA were required; to prevent loss, 2 ml of each was prepared).

[0092] (3) The solvent is transferred from one syringe to another and mixed thoroughly for at least 10 minutes. Good emulsification is a key step. After emulsification is completed, close the three-way valve (the emulsion should be white, hard and viscous, without phase separation. When dropped into clean water, it floats on the water surface without dispersion). After preparing the emulsion, wait at least 30 minutes to observe whether the emulsion is stable.

[0093] 1.2 Animal immunization

[0094] (1) Anesthetize the mouse (assess the level of anesthesia by pinching the toe).

[0095] (2) Subcutaneously inject 100 μl of the antigen peptide emulsion into two different locations on the hind flank of the mouse (the needle remains in the body for 15 seconds after injection, and a spherical mass should form under the mouse's skin and remain there throughout the experiment).

[0096] (3) During the entire experiment, mark the tail of each mouse and record the changes in blood sugar levels.

[0097] 1.3 Isolation and extraction of T cells

[0098] Using STEMCELL's EasySep TM Mouse T Cell Isolation Kit was used to isolate T cells according to the instructions in the manual. The experimental steps are as follows:

[0099] (1) Adjust the concentration of lymphocyte suspension to 1×10^8 cells / mL and take 1-1.5 ml.

[0100] (2) Add rat serum at a ratio of 50 μl / ml and mix well using a pipette.

[0101] (3) Add T Cell Isolation Cocktail at a ratio of 50 μl / ml, mix well with a pipette, and incubate at room temperature for 10 min.

[0102] (4) Add Streptavidin RapidSpheres at a concentration of 75 μl / ml TM The beads were mixed and the volume was supplemented to 2.5 ml with buffer (1×PBS+2% FBS), placed on a magnetic stand, and incubated at room temperature for 2.5 min.

[0103] (5) Transfer the supernatant to a new flow cytometry tube (5 ml), place the flow cytometry tube containing the cell supernatant on a magnetic rack, and incubate at room temperature for 2.5 min.

[0104] (6) Collect the supernatant into a new centrifuge tube and centrifuge at 4°C, 1500 rpm for 10 min. Discard the supernatant.

[0105] (7) Add buffer (1×PBS+2% FBS) to resuspend the cells and collect the T cells, which are the T cell population obtained by GAD immunization.

[0106] 1.4 Isolation of antigen-specific T cells

[0107] 1. Resuspend the collected T cells in the flow cytometer buffer (FACS Buffer) at a density of 2-5x10^7 / ml to prepare a single cell suspension. FACS Buffer is composed of 1×PBS+2% calf serum+0.1% sodium azide and is prepared and used immediately. Take 25ul of cell suspension and add it to a 5ml FACS tube to obtain T cell subsets containing CD4 / CD8 T cells.

[0108] 2. Preparation of Staining Cocktail: Take 10 μl of MHC-antigen peptide tetramer and dilute it 50 times by adding FACS Buffer. The antigen peptide sequence is shown in SEQ ID NO.1.

[0109] 3. Staining and incubation: Take 25 μl of Staining Cocktail and add it to the FACS tube containing the cell suspension. Mix it gently by pipetting and avoid generating bubbles as much as possible.

[0110] 4. Incubate on ice or in a 4°C refrigerator, away from light for 60 minutes.

[0111] 5. Washing: Add 150ul FACS Buffer to the FACS tube in step 4, mix gently to avoid forming bubbles, centrifuge at 1200rpm for 5min, and carefully remove the supernatant without touching the cell pellet to reduce cell loss.

[0112] 6. Repeat step 5 and wash twice. Use magnetic beads with PE-specific antibodies to sort out cells that are positive for PE-labeled tetramer staining. The resulting positive cells are CD8 T cells.

[0113] Example 2 Adoptive transfer combined with STZ to induce T1DM

[0114] The inventors' previous studies have confirmed that the cell population induced by immunization with GAD antigen peptide alone in C57BL / 6 mice cannot induce T1DM. Therefore, in this example, STZ combined with T cell adoptive transfer therapy was used to induce T1DM.

[0115] 2.1 Mouse grouping and treatment

[0116] Ten mice of about 8 weeks old were randomly divided into AT (Adoptive transfer) group and PBS group, and the blood glucose of mice was recorded as the blood glucose at day 0. The two groups of mice were treated as follows:

[0117] AT group: 200 μl containing 5×10^6 T cells were adoptively transferred into C57BL / 6 mice via tail vein injection, and 40 mg / kg STZ solution was intraperitoneally injected on the 2nd and 3rd day respectively.

[0118] PBS group: 200 μl PBS solution was injected into C57BL / 6 mice through the tail vein, and 40 mg / kg STZ solution was injected intraperitoneally on the 2nd and 3rd day, respectively.

[0119] 2.2 Blood glucose testing

[0120] The mouse was taken out of the cage and gently placed on the iron grid. The tail of the mouse was cut off by about 1-2 mm with surgical scissors, and the tail was gently squeezed to concentrate the blood into a drop of blood. The blood glucose of the mouse was tested with a Roche blood glucose monitor.

[0121] Results: Figure 1 As shown in the figure, after 17 days, the mice in the AT group began to show symptoms of hyperglycemia, while the blood sugar in the PBS group was normal. When the blood sugar concentration was greater than 13.8mmol / L for two consecutive days, the mice were considered to have developed T1DM.

[0122] 2.3 Immunofluorescence staining

[0123] In order to further examine the presence of pancreatic β cells in mice with hyperglycemia and whether the mice have pathological characteristics of T1DM, in this example, an immunofluorescence staining experiment of pancreatic tissue was performed to detect the infiltration of pancreatic T cells and the survival of β cells. The method is as follows:

[0124] (1) After euthanasia, mice were immersed in 75% ethanol and pancreatic tissue was obtained from the ventral side.

[0125] (2) Fix with 4% PFA in a 4°C refrigerator overnight.

[0126] (3) Then, the pancreatic tissue was dehydrated with 30% sucrose solution until it was completely precipitated in the solution.

[0127] (4) Remove the completely settled pancreatic tissue from the 30% sucrose solution and place it on filter paper to carefully absorb the surface liquid. Rinse once with 1× PBS solution and absorb the liquid, then embed the pancreatic tissue in OCT. Place the embedded tissue in a 4°C refrigerator for 15-30 minutes to eliminate bubbles, freeze the embedded tissue in a -80°C refrigerator for 30 minutes, and store the frozen tissue in -20°C ice.

[0128] (5) When slicing, take it out and fix it on the stage of the freezing microtome. Select the tissue you want to slice. The slice thickness is 7 μm.

[0129] (6) After the slices are dried at room temperature, rinse the tissue sections in 1× PBS solution for 5-10 minutes.

[0130] (7) Place the slice in 0.3% PBST solution for 30 minutes to break the membrane (1*PBS contains 0.3% Tritonx100, Tritonx100 is viscous, pay attention to the gun tip and usage when preparing it to prevent clogging of the gun tip).

[0131] (8) Shake off the residual liquid, wipe off the liquid around the tissue with a paper towel, circle the slide with the tissue with a histology pen, place it in a dark box, add 10% FBS and block it at room temperature for 2 hours.

[0132] (9) Discard the blocking solution from the blocked slides, wipe off the excess liquid with a paper towel, and keep the circle of the histochemical pen intact. Add anti-glucagon (abcam), anti-CD3 (CST), and MAFA antibody (CST) as primary antibodies and incubate overnight at 4°C.

[0133] (10) Rinse tissue sections three times with 1× PBS, each time for 10 min.

[0134] (11) Add fluorescent secondary antibody of the same species as the primary antibody and incubate at 37°C in the dark for 2 hours.

[0135] (12) After incubation with the secondary antibody, rinse the tissue sections five times in 1× PBS in the dark for 7 min each time and air dry.

[0136] (13) Apply a sealing agent containing DAPI to seal the slide and dry it in the dark.

[0137] (14) Fluorescence observation and analysis were performed on a laser confocal microscope. The corresponding laser channels (405, 488, and 633 nm, respectively) were selected according to the fluorescent secondary antibody for fluorescence observation and analysis.

[0138] Results: MAFA is a transcription factor for pancreatic β cells in mice, which is specifically expressed in β cells and is a β cell marker. Anti-MAFA was used to label β cells to evaluate the presence of mouse β cells. The number of pancreatic β cells in normal mice generally accounts for about 80% of the entire pancreatic cells. The mice in the AT group had a large loss of pancreatic β cells, while the percentage of β cells in the PBS group was normal ( Figure 2 ).

[0139] This result shows that the STZ dose used in the present invention does not cause significant damage to the pancreatic β cells of mice. Therefore, the constructed model is basically only caused by T cell autoimmunity to cause pancreatic β cell destruction, which more realistically simulates the pathogenesis of T1DM.

[0140] 2.4 Pancreatic T cell infiltration

[0141] Anti-CD3 antibody was used to label T cells and observe T cell infiltration in pancreatic islet tissue. It was found that there was no immune cell infiltration in the pancreatic tissue of mice in the PBS group, while immune cells infiltrated the pancreatic islet tissue in the AT group, forming pancreatitis ( Figure 3 ).

[0142] It can be found that immune cell infiltration and β-cell loss were found in the tissues of T1DM mice, indicating that the model meets the T1DM model conditions in terms of physiology (hyperglycemia) and pathology (insulitis).

[0143] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for preparing a non-human mammal model of type 1 diabetes, characterized in that: The animal is a non-immunodeficient animal, and the method comprises administering to the animal T cells that specifically target GAD.

2. The preparation method according to claim 1, characterized in that The animals are C57BL / 6 mice.

3. The preparation method according to claim 1, characterized in that: The T cells specifically targeting GAD specifically bind to the antigen epitope peptide shown as AFLHATDLL (SEQ ID NO.1).

4. The preparation method according to claim 1, characterized in that: The T cells are CD8 + T cells.

5. The preparation method according to claim 1, characterized in that: The T cells are prepared by the following method: A cell population is provided which is immunostimulated with a GAD antigen peptide, and T cells are isolated from the cell population.

6. Use of the animal model prepared by the method of claim 1, characterized in that: Used to study the pathogenesis of T1DM.

7. Use of the animal model prepared by the method according to claim 1, characterized in that: Used to screen or identify substances that can prevent or treat T1DM.

8. A method for preparing GAD-specific T cells, characterized in that: The method comprises the steps of: 1) providing a cell population stimulated by GAD immunotherapy, and isolating a T cell population from the cell population; 2) isolating T cells that specifically bind to the antigen peptide shown in SEQ ID NO.1 from the T cell population.

9. The preparation method according to claim 8, characterized in that: The T cells are CD8 + T cells.

10. A composition for preparing a T1DM non-human mammal model, characterized in that: The composition comprises: M1) T cells that specifically target GAD; and M2) Other substances that induce T1DM.

Citation Information

Patent Citations

  • Construction method of new animal model of type 1 diabetes mellitus

    CN112933211A

  • Regulatory T cells suppress autoimmunity

    CN1953767A

  • Method of enhancing T cell immunity by selection of antigen specific T cells

    US20030021796A1

  • Method and compositions for treatment of insulin-dependant diabetes mellitus

    US20050025758A1

  • Spontaneous Autoimmune Diabetes in Humanized Mice Carrying Human Type 1 Diabetes Susceptibility and Uses Therefor

    US20200037586A1